 |
BioWorld-International-2009-11-11
Biovitrum Will Pay up to $533M for Swedish Orphan
Biovitrum Will Pay up to $533M for Swedish Orphan
Biovitrum AB has taken a significant step in its goal to become a fully integrated, specialty pharmaceutical firm focused on niche indications, with an SEK3.656 billion (US$533.1 million) cash-and-shares acquisition of Swedish Orphan International AB. (BioWorld International)